BioNTech ends Phase 2 colorectal cancer trial

Empty oncology treatment chair in hospital infusion room after halted colorectal cancer trial for BNTX

Key Points

01BioNTech (BNTX) has ended its Phase 2 BNT122-01 colorectal cancer trial
02A monitoring board saw an overall survival imbalance between treatment arms
03The study was deemed unlikely to change its efficacy outcome if continued
04BioNTech (BNTX) shares fell sharply intraday after the announcement

BioNTech halts mid-stage colorectal cancer trial

BioNTech (BNTX) has stopped its Phase 2 BNT122-01 trial evaluating autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients. The study focused on ctDNA-positive, surgically resected high‑risk Stage II (high‑risk) or Stage III colorectal cancer, assessing whether the individualized mRNA immunotherapy could improve outcomes after surgery.

The company decided to terminate the trial following a scheduled review of data by an independent Data Safety Monitoring Board. That review led to a recommendation to discontinue treatment and end the study.

Data review and DSMB recommendation

The Data Safety Monitoring Board examined the latest available efficacy data from the BNT122-01 trial and identified a numerical imbalance in overall survival between the treatment and control arms. Based on this assessment, the board concluded that continuing the trial was unlikely to change the overall efficacy outcome.

In light of this recommendation, BioNTech and its partner Genentech agreed to terminate the trial. The company has indicated it will carry out a detailed analysis of the collected data to better understand patient selection and guide future development of mRNA cancer immunotherapies.

Market reaction to the trial termination

News of the trial’s termination prompted a negative reaction in financial markets. One set of reports stated that BioNTech shares tumbled about 10% intraday following the announcement, highlighting investor sensitivity to clinical developments in the company’s oncology pipeline.

The share-price move underscored how pivotal oncology programs such as autogene cevumeran are perceived within BioNTech’s broader portfolio, which also includes other mRNA-based therapies.

Ongoing development of autogene cevumeran

While the BNT122-01 colorectal cancer study has been halted, development of autogene cevumeran is continuing in other indications. Reports state that a separate Phase 2 trial evaluating the therapy in combination with checkpoint inhibition and chemotherapy for pancreatic cancer is not affected and will proceed as planned.

BioNTech’s planned in-depth analysis of the BNT122-01 data is expected to inform how it designs future mRNA oncology studies, including approaches to choosing appropriate patient populations and treatment settings.

Key Takeaways

01The mid-stage colorectal cancer trial was halted for lack of likely efficacy benefit rather than operational reasons, reshaping expectations for that program.
02An observed imbalance in overall survival between treatment and control arms was central to the decision to end the BNT122-01 study.
03The sharp share-price reaction shows that investors closely link BioNTech’s valuation to progress in its mRNA oncology pipeline beyond infectious disease vaccines.

References